De mest almindelige bivirkninger, der blev anset for at være relateret til administration af 2 x 1000 mg MabThera i fase- II og fase- III studier, var akutte infusionsreaktioner.
The most frequent adverse reactions considered due to receipt of 2x1000 mg MabThera in Phase II and III studies were acute infusion reactions.